Metformin Stada (Metformin Hydrochloride)

• Metformin Stada belongs to the biguanide class and is indicated for conditions related to impaired glucose regulation.
• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
• Prediabetes: delays progression to overt type 2 diabetes.
• Polycystic ovary syndrome (PCOS): improves insulin resistance and may aid menstrual regularity.

• Metformin Hydrochloride decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and enhances peripheral insulin sensitivity by activating AMP‑activated protein kinase (AMPK). These actions collectively lower circulating glucose without stimulating insulin secretion.

Metformin Stada may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Nausea or upset stomach
• Diarrhea or loose stools
• Metallic taste in the mouth
• Abdominal discomfort or cramping
• Weight loss or reduced appetite
• Vitamin B12 deficiency with long‑term use

Serious or Rare Side Effects

• Lactic acidosis, a medical emergency
• Severe skin reactions such as Stevens‑Johnson syndrome
• Hepatotoxicity or liver enzyme elevation
• Hypoglycemia when combined with other antidiabetics
• Acute pancreatitis
• Anemia or hemolytic events

• Before initiating Metformin Stada, several safety considerations should be observed.
• Renal function assessment: ensure adequate kidney function before use.
• Hepatic status evaluation: avoid in patients with significant liver disease.
• Lactic acidosis risk: discontinue if signs of hypoxia, sepsis, or severe dehydration occur.
• Elderly monitoring: adjust dose and monitor for accumulation.
• Concomitant medication review: assess for drugs that may impair renal clearance.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Stada can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Iodinated contrast agents: risk of acute renal failure.
• Cimetidine: may increase metformin plasma concentrations.
• Alcohol excess: heightens lactic acidosis risk.
• Diuretics that reduce renal perfusion.
• Nifedipine: may affect glucose control.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms.
• ACE inhibitors or ARBs: monitor renal function.
• Other antidiabetic agents: adjust dosing to prevent hypoglycemia.
• Warfarin: may alter INR values.
• Digoxin: monitor for potential toxicity.